Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: An analysis of cytokeratin 20, p53, and CD44 antigens

American Journal of Surgical Pathology

Volumn 25, Issue 8, 2001, Pages 1074-1078

  McKenney, Jesse K ^a   Desai, Sangeeta ^a   Cohen, Cynthia ^a   Amin, Mahul B ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Carcinoma in situ; CD44; Cytokeratin 20; Immunohistochemistry; Intraepithelial lesions; P53; Reactive atypia; Urinary bladder

Indexed keywords

CYTOKERATIN 20; HERMES ANTIGEN; PROTEIN P53;

ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; NEPHRECTOMY; PROTEIN EXPRESSION;

ANTIGENS, CD44; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOENZYME TECHNIQUES; INTERMEDIATE FILAMENT PROTEINS; KERATIN-20; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0034941337     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200108000-00013     Document Type: Article

References (36)

1. Intraepithelial lesions of the urothelium: An interobserver reproducibility study with proposed terminology and histologic criteria
2. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44
3. Forms and functions of CD44
4. Natural history of early bladder cancer
5. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells
6. Rhokinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells
7. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases
8. Cellular adhesion molecules in urologic malignancies
9. Alterations of tumor suppressor genes in bladder cancer
10. Survival of patients with carcinoma in situ of the urinary bladder
11. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia
12. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder
13. Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder
14. Current status of CD44 variant isoforms as cancer diagnostic markers
15. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: A potential for distinguishing recurrent from non-recurrent disease
16. Cytokeratin 20 as an objective marker of urothelial dysplasia
17. Increased expression of mutant forms of p53 oncogene in primary lung cancer
18. Molecular genetics of bladder cancer
19. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer
20. The p53 turnout suppressor gene
21. N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding
22. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumors and their relation to prognosis during a long term follow-up
23. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer: Occurrence of false-positives and false negatives
24. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities
25. Morphologic expressions of urothelial carcinoma in situ: A detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion
26. Cytokeratin 20 in human carcinomas: A new histodiagnostic marker detected by monoclonal antibodies
27. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma
28. CD44 and the adhesion of neoplastic cells
29. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder
30. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons
31. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor: Comparison of all 10 variable exons between mouse, human, and rat
32. Identification of p53 gene mutations in bladder cancers and urine samples
33. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis
34. Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma
35. Suits & briefs
36. Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia